Morphic to Present at the 41st Annual J.P. Morgan Healthcare Conference

Morphic Therapeutic (Nasdaq: MORF) will have CEO Praveen Tipirneni present at the 41st Annual J.P.

Rhea-AI Summary

Morphic Therapeutic (Nasdaq: MORF) will have CEO Praveen Tipirneni present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 2:15 PM PST. The presentation will focus on the company’s innovative oral integrin therapies aimed at treating serious chronic diseases, including autoimmune and cardiovascular disorders.

A live webcast will be accessible on Morphic’s investor website, with an archived replay available afterward.

Argus Session date unavailable

+1.15% session move Open Argus

Details

News Market Reaction – MORF

The recorded move for MORF in the trading session of this news was +1.15%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WALTHAM, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Praveen Tipirneni, M.D., President and Chief Executive Officer, will present at the 41^st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 2:15 PM PST.

A live webcast of the presentation will be available on the Investor section of Morphic’s website at www.morphictx.com. An archived replay will be available on the company’s website following the conference.

About Morphic Therapeutic
Morphic Therapeutic is a biopharmaceutical company developing a portfolio of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis, and cancer. Morphic is also advancing its pipeline and discovery activities in collaborations with Janssen and Schrödinger using its proprietary MInT technology platform which leverages the Company’s unique understanding of integrin structure and biology. For more information, visit www.morphictx.com.

Contacts
Morphic Therapeutic
Chris Erdman
chris.erdman@morphictx.com
617.686.1718

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Morphic Therapeutic's presentation at the J.P. Morgan Healthcare Conference?

Morphic Therapeutic's presentation will take place on January 11, 2023, at 2:15 PM PST.

Who is presenting for Morphic Therapeutic at the conference?

Praveen Tipirneni, M.D., the CEO of Morphic Therapeutic, will be presenting.

How can I watch the Morphic Therapeutic presentation?

The presentation can be watched live on the investor section of Morphic’s website.

What are Morphic Therapeutic's main areas of focus?

Morphic Therapeutic focuses on developing oral integrin therapies for serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases.

What technology does Morphic Therapeutic utilize in its drug development?

Morphic Therapeutic uses its proprietary MInT technology platform for drug development.